| Filed On | Filing |
|---|---|
| 29 Jul 2025 |
8-K/A: Other Events
LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – |
| 23 May 2023 |
8-K/A: Financial Statements and Exhibits
On May 17, 2023 (the “Closing Date”), EyePoint Pharmaceuticals, Inc. (the “Company”) entered into a product rights agreement (the “Product Rights Agreement”) with Alimera Sciences, Inc. (“Alimera”) to grant to Alimera an exclusive (even ... |
| 12 Jan 2022 | 8-K/A: Other Events |
| 16 Jan 2020 | 8-K/A: Other Events |
| 09 Sep 2019 | 8-K/A: Submission of Matters to a Vote of Security Holders |
| 11 Jun 2018 | 8-K/A: Completion of Acquisition or Disposition of Assets; Other Events |
Loading...
